嵌合抗原受体
细胞疗法
过继性细胞移植
体内
癌症研究
免疫学
医学
癌症
T细胞
离体
细胞
生物
免疫系统
内科学
生物技术
遗传学
作者
Garima Kaushik,Shivaprasad H. Venkatesha,Bhavna Verma,Bandana Ajay Vishwakarma,Ai-Hong Zhang,Amy Wesa
出处
期刊:The cancer journal
[Ovid Technologies (Wolters Kluwer)]
日期:2022-07-01
卷期号:28 (4): 257-262
被引量:3
标识
DOI:10.1097/ppo.0000000000000609
摘要
Abstract Adoptive cellular therapies are making major strides in the treatment of cancer, both for hematologic and solid tumors. These cellular products include chimeric antigen receptor T cells and T-cell receptor–modified T cells, tumor-infiltrating lymphocytes, marrow-infiltrating T cells, natural killer cells as well as macrophage-based therapeutics. Advancement in genomics, computational biology, immunology, and cell therapy manufacturing has facilitated advancement of adoptive T cell therapies into the clinic, whereas clinical efficacy has driven Food and Drug Administration approvals. The growth of adoptive cellular therapy has, in turn, led to innovation in the preclinical models available, from ex vivo cell-based models to in vivo xenograft models of treatment. This review focuses on the development and application of in vitro models and in vivo models (cell line xenograft, humanized mice, and patient-derived xenograft models) that directly evaluate these human cellular products.
科研通智能强力驱动
Strongly Powered by AbleSci AI